17191-52-5

Basic information

• Product Name: Pentanoic acid, 5-amino-5-oxo-4-[[(phenylmethoxy)carbonyl]amino]-, 1,1-dimethylethyl ester, (S)-
• CAS NO: 17191-52-5
• Molecular Formula: C17H24N2O5
• Molecular Weight: 336.388
• Mol File: 17191-52-5.mol
• Article Data: 15

Chemical Properties

• CAS DataBase Reference: Pentanoic acid, 5-amino-5-oxo-4-[[(phenylmethoxy)carbonyl]amino]-, 1,1-dimethylethyl ester, (S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Pentanoic acid, 5-amino-5-oxo-4-[[(phenylmethoxy)carbonyl]amino]-, 1,1-dimethylethyl ester, (S)-(17191-52-5)
• EPA Substance Registry System: Pentanoic acid, 5-amino-5-oxo-4-[[(phenylmethoxy)carbonyl]amino]-, 1,1-dimethylethyl ester, (S)-(17191-52-5)

Safety Data

• Hazardous Substances Data: 17191-52-5(Hazardous Substances Data)

Upstream product

• 23632-67-9 (S)-3-[3-(benzyloxycarbonyl)-5-oxooxazolidin-4-yl]propanoic acid 
• 501-53-1 benzyl chloroformate 
• 71432-55-8 2-tert-butyl-1,3-diisopropylisourea 
• 6398-06-7 N-benzyloxycarbonyl-L-isoglutamine 
• 56-86-0 L-glutamic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 3886-08-6 5-tert-butyl N-benzyloxycarbonyl-L-glutamate 
• 1155-62-0 N-benzyloxycarbonyl-L-glutamic acid 
• 540-88-5 acetic acid tert-butyl ester 
• 56877-41-9 methyl 2(S)-2-benzyloxycarbonylamino-4-tert-butoxycarbonylbutanoate 
• 4124-76-9 N-(benzyloxycarbonyl)-L-glutamic acid anhydride 
• 5672-83-3 Z-L-GluOMe 

Relevant articles and documents

NosN, a Radical S-Adenosylmethionine Methylase, Catalyzes Both C1 Transfer and Formation of the Ester Linkage of the Side-Ring System during the Biosynthesis of Nosiheptide

Nosiheptide, a member of the e series of macrocyclic thiopeptide natural products, contains a side-ring system composed of a 3,4-dimethylindolic acid (DMIA) moiety connected to Glu6 and Cys8 of the thiopeptide backbone via ester and thioester linkages, re

METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS

The present application relates to treating and/or preventing breast cancer, including locally advanced or metastatic, ER+, HER2? breast cancer, in a subject in need of treatment, comprising administering a compound of Formula (I), or a pharmaceutically a

PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE AND METHODS OF USING THE SAME

Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, mixture of enantiomers, t